Ixazomib
As of the edition of 20 October 2026, Ixazomib is a small molecule: marketed, first approved in 2015 (US); acts on PSMB5; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Ninlaro
- First approved
- 20 November 2015 (US)
- Approvals on record
- 12 in 5 regions
- Holder of the most recent approval
- Takeda
- Registered trials
- 101, 30 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PSMB5 | Proteasome subunit beta type-5 | P28074 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 0 |
| Phase 1 | 20 | 14 | 0 | 6 |
| Phase 2 | 66 | 26 | 13 | 20 |
| Phase 3 | 6 | 4 | 0 | 2 |
| Phase 4 | 6 | 2 | 1 | 2 |
| All trials | 101 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Originator, Applicant and Lead sponsor of trials | 2009 to now |